IL128456D0 - Compositions containing a Rho kinase inhibitor - Google Patents

Compositions containing a Rho kinase inhibitor

Info

Publication number
IL128456D0
IL128456D0 IL12845697A IL12845697A IL128456D0 IL 128456 D0 IL128456 D0 IL 128456D0 IL 12845697 A IL12845697 A IL 12845697A IL 12845697 A IL12845697 A IL 12845697A IL 128456 D0 IL128456 D0 IL 128456D0
Authority
IL
Israel
Prior art keywords
compositions containing
kinase inhibitor
rho kinase
rho
inhibitor
Prior art date
Application number
IL12845697A
Original Assignee
Yoshitomi Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to JP21240996 priority Critical
Application filed by Yoshitomi Pharmaceutical filed Critical Yoshitomi Pharmaceutical
Priority to PCT/JP1997/002793 priority patent/WO1998006433A1/en
Publication of IL128456D0 publication Critical patent/IL128456D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16622116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL128456(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
IL12845697A 1996-08-12 1997-08-08 Compositions containing a Rho kinase inhibitor IL128456D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP21240996 1996-08-12
PCT/JP1997/002793 WO1998006433A1 (en) 1996-08-12 1997-08-08 MEDICINES COMPRISING Rho KINASE INHIBITOR

Publications (1)

Publication Number Publication Date
IL128456D0 true IL128456D0 (en) 2000-01-31

Family

ID=16622116

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12845697A IL128456D0 (en) 1996-08-12 1997-08-08 Compositions containing a Rho kinase inhibitor

Country Status (26)

Country Link
US (3) US6218410B1 (en)
EP (1) EP0956865B2 (en)
JP (1) JP3669711B2 (en)
KR (2) KR100595740B1 (en)
CN (1) CN100389828C (en)
AT (1) AT359822T (en)
AU (1) AU738620B2 (en)
BG (4) BG107195A (en)
BR (1) BR9711154A (en)
CA (1) CA2263425C (en)
CZ (1) CZ301044B6 (en)
DE (2) DE69737631D1 (en)
DK (1) DK0956865T4 (en)
EE (1) EE9900050A (en)
ES (1) ES2286834T5 (en)
HK (1) HK1022436A1 (en)
HU (1) HU229864B1 (en)
IL (1) IL128456D0 (en)
IS (1) IS4973A (en)
NO (1) NO990622L (en)
NZ (2) NZ513800A (en)
PL (1) PL331561A1 (en)
PT (1) PT956865E (en)
RU (3) RU2206321C2 (en)
SI (1) SI0956865T2 (en)
WO (1) WO1998006433A1 (en)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE9900050A (en) * 1996-08-12 1999-08-16 Yoshitomi Pharmaceutical Industries, Ltd. A pharmaceutical agent containing a Rho kinase inhibitor
CA2327276A1 (en) * 1998-04-23 1999-10-28 Hiroshi Muramatsu Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
US20080233098A1 (en) * 1997-10-31 2008-09-25 Mckerracher Lisa RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
ES2372572T3 (en) * 1998-08-17 2012-01-23 Mitsubishi Tanabe Pharma Corporation Agent for profilaxis and treatment of glaucoma.
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
AT374026T (en) * 1999-03-25 2007-10-15 Mitsubishi Pharma Corp Rho kinase inhibitors for preventing or treating interstitial pneumonia and pulmonary fibrosis
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
CA2369552A1 (en) * 1999-04-22 2000-11-02 Hisashi Kai Agent for prophylaxis and treatment of angiostenosis
ES2365692T3 (en) * 1999-04-27 2011-10-10 Mitsubishi Tanabe Pharma Corporation Medicinal for the prevention or therapeutic treatment of hepatic diseases.
KR100812972B1 (en) * 1999-04-27 2008-03-13 미쯔비시 웰 파마 가부시키가이샤 Preventives/remedies for liver diseases
WO2000078351A1 (en) * 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
JP2001081031A (en) * 1999-08-30 2001-03-27 Schering Ag Benzamide derivative-containing preparation having improved solubility and oral adsorption
WO2001017562A1 (en) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Osteogenesis promoting agents
AU7451200A (en) * 1999-09-29 2001-04-30 Mitsubishi Pharma Corporation Analgesics
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
CN1198804C (en) * 2000-03-16 2005-04-27 三菱制药株式会社 Amide compounds and use thereof
KR100818060B1 (en) * 2000-03-16 2008-03-31 미쯔비시 웰 파마 가부시키가이샤 Amide compounds and use thereof
CA2404594C (en) 2000-03-31 2010-12-21 Mitsubishi Pharma Corporation Agent for prophylaxis and treatment of renal disease
ES2344831T3 (en) 2000-06-23 2010-09-08 Mitsubishi Tanabe Pharma Corporation Potentials of an antitumoral effect.
CA2422488A1 (en) * 2000-09-20 2002-03-28 Merck Patent Gesellschaft Mit Beschraenkter Haftung 4-amino-quinazolines
CA2422560A1 (en) * 2000-09-20 2002-03-28 Merck Patent Gesellschaft Mit Beschraenkter Haftung 4-amino-quinazolines
US7829566B2 (en) * 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
JP4582561B2 (en) * 2000-10-23 2010-11-17 旭化成ファーマ株式会社 Inhibitor of vascular lesions caused by transplantation
JP2002139493A (en) * 2000-11-01 2002-05-17 Sumitomo Pharmaceut Co Ltd Novel high throughput screening method
CA2325842C (en) * 2000-11-02 2007-08-07 Lisa Mckerracher Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
WO2002053143A2 (en) * 2001-01-05 2002-07-11 The Medical College Of Georgia Research Institute, Inc. Treatment of erectile dysfunction with rho-kinase inhibitors
JP2002226375A (en) * 2001-01-31 2002-08-14 Asahi Kasei Corp Agent for preventing and treating fibrosis
US20030068320A1 (en) * 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
TWI336328B (en) * 2001-03-23 2011-01-21 Bayer Healthcare Llc Rho-kinase inhibitors
US7645878B2 (en) * 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
PE20021011A1 (en) * 2001-03-23 2003-02-01 Bayer Corp Quinazolinicos derivatives as inhibitors of rho kinase
JP4204326B2 (en) 2001-04-11 2009-01-07 千寿製薬株式会社 Visual function disorder improving agent
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
JP5042419B2 (en) * 2001-08-15 2012-10-03 旭化成ファーマ株式会社 Bone formation promoter and composition for promoting bone formation
DE10153605A1 (en) * 2001-11-02 2003-05-28 Morphochem Ag Komb Chemie Use of inhibitors of Rho kinases to stimulate nerve growth, to inhibit scar tissue formation and / or to reduce secondary damage
AU2002349411A1 (en) * 2001-11-30 2003-06-17 Asahi Kasei Pharma Corporation Remedies for primary pulmonary hypertension
CA2472619A1 (en) * 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
MXPA04007191A (en) * 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Pyrimidine derivatives as rho-kinase inhibitors.
JP4423043B2 (en) * 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Rho-kinase inhibitor
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
JPWO2003082808A1 (en) * 2002-04-03 2005-08-04 住友製薬株式会社 Benzamide derivatives
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040028716A1 (en) * 2002-06-14 2004-02-12 Marks Andrew R. Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CN1681525A (en) * 2002-07-12 2005-10-12 曹义海 A method for inhibiting vascular permeability and tissue edema
US7094789B2 (en) 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
CN100354264C (en) * 2002-07-22 2007-12-12 旭化成制药株式会社 5-substituted isoquinoline derivatives
DE10233737A1 (en) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Use of modulators of the signal transduction pathway via the protein kinase Fyn for the treatment of tumor diseases
AU2003257960A1 (en) * 2002-08-01 2004-03-03 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Cell modulation using a cytoskeletal protein
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
CA2400996A1 (en) * 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
US7615564B2 (en) * 2002-09-12 2009-11-10 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
US20050215601A1 (en) * 2002-09-25 2005-09-29 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4314433B2 (en) 2002-11-18 2009-08-19 参天製薬株式会社 Glaucoma treatment agent comprising Rho kinase inhibitor and β-blocker
AU2003901270A0 (en) * 2003-03-18 2003-04-03 Medvet Science Pty. Ltd. A method of modulating muscle cell functioning
AU2004221792C1 (en) * 2003-03-18 2009-09-24 Medvet Science Pty. Ltd. A method of modulating smooth muscle cell functioning by modulating sphingosine kinase mediated signalling
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
JP4566130B2 (en) * 2003-04-18 2010-10-20 千寿製薬株式会社 Corneal sensory recovery agent
US20040266755A1 (en) * 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
US20110098232A1 (en) * 2003-05-30 2011-04-28 Zeilig Charles E Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis
WO2004108142A2 (en) * 2003-06-06 2004-12-16 The University Of Manchester Inhibitors of tip-1 for treatment tissue damage
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2005017161A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
WO2005017160A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US7371850B1 (en) 2003-08-20 2008-05-13 Myriad Genetics, Inc. Method and composition for reducing expression of ROCK-II
KR101163800B1 (en) 2003-10-15 2012-07-09 산텐 세이야꾸 가부시키가이샤 Novel indazole derivative
US20050238666A1 (en) * 2003-12-05 2005-10-27 Williams David A Methods of enhancing stem cell engraftment
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
SI1696958T1 (en) * 2003-12-22 2007-08-31 Alcon Inc Agents for treatment of glaucomatous retinopathy and optic neuropathy
TW200526224A (en) * 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
CA2548146A1 (en) * 2003-12-22 2005-07-14 Alcon, Inc. Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
CN1980929A (en) * 2004-02-24 2007-06-13 比奥阿克松医疗技术股份有限公司 4-substituted piperidine derivatives
WO2005094824A1 (en) * 2004-03-25 2005-10-13 East Carolina University Methods of enhancing cancer therapy by protecting nerve cells
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
US20060115870A1 (en) * 2004-03-30 2006-06-01 Alcon, Inc. High throughput assay for human Rho kinase activity
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
PL1734996T3 (en) 2004-04-02 2013-09-30 Univ California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
CN1795196B (en) * 2004-06-03 2013-07-24 千寿制药株式会社 Use of amide in preparing compound agent for repairing corneal sensitivity
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
FR2879100B1 (en) 2004-12-09 2007-07-06 Lionel Bueno Compositions for the treatment of ocular surface pathologies and retina
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp Pyrrolo [2,3-b] pyridin-4-yl-amines and pyrrolo [2,3-b] pyrimidin-4-yl-amines as inhibitors of janus kinases. pharmaceutical compositions.
JP2008525453A (en) * 2004-12-27 2008-07-17 アルコン,インコーポレイティド Aminopyrazine analogs for treating glaucoma and other diseases and conditions mediated by rho kinase
JP4895219B2 (en) * 2005-02-16 2012-03-14 アステラス製薬株式会社 Pain treatment agent containing ROCK inhibitor
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
CR9465A (en) 2005-03-25 2008-06-19 Surface Logix Inc Pharmacokinetically improved compounds
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
RU2443688C2 (en) * 2005-06-28 2012-02-27 Санофи-Авентис ISOQUINOLINE DERIVATIVES AS Rho-KINASE INHIBITORS
AU2006274246B2 (en) 2005-07-26 2012-07-12 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors
ES2423006T3 (en) 2005-07-26 2013-09-17 Sanofi Piperidinyl substituted isoquinolone derivatives as Rho kinase inhibitors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CN101253166B (en) 2005-08-30 2013-07-10 旭化成制药株式会社 Sulfonamide compound
KR20080040027A (en) 2005-09-02 2008-05-07 아스테라스 세이야쿠 가부시키가이샤 Amide derivatives as rock inhibitors
JP4832051B2 (en) * 2005-10-21 2011-12-07 学校法人順天堂 Treatment for crescent-forming kidney lesions
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007050783A2 (en) * 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US7655662B2 (en) * 2005-12-22 2010-02-02 Alcon Research, Ltd. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JPWO2007142323A1 (en) 2006-06-08 2009-10-29 宇部興産株式会社 A novel indazole derivative having a spiro ring structure in the side chain
BRPI0714782A2 (en) * 2006-07-31 2013-07-16 Senju Pharma Co aqueous liquid preparation containing amide compound
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
EA021255B1 (en) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Antagonistic human light-specific human monoclonal antibodies
GB0617222D0 (en) * 2006-08-31 2006-10-11 Vereniging Het Nl Kanker I Antibiotics
KR20090064418A (en) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008049000A2 (en) * 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (en) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Ophthalmic pharmaceutical compositions comprising an effective amount of 6-aminoimidazo analogs [1,2b] pyridazines, useful for treating glaucoma and / or controlling intraocular pressure normal or elevated (iop).
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
BRPI0720862A2 (en) 2006-12-27 2014-02-25 Sanofi Aventis Isokinoline and isoquinolinone derivatives replaced as rho-kinase inhibitors
DE602007013295D1 (en) 2006-12-27 2011-04-28 Sanofi Aventis Substituted isochinolines and their use as rho kinase inhibitors
DK2102164T3 (en) 2006-12-27 2011-03-21 Sanofi Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
EP2125746B1 (en) 2006-12-27 2012-04-18 Sanofi Cycloalkylamine substituted isoquinoline derivatives
WO2008077551A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinolone derivatives
CA2675445C (en) * 2007-01-17 2014-11-04 Wisconsin Alumni Research Foundation Improved culture of stem cells
WO2008105058A1 (en) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation Sulfonamides
WO2008105442A1 (en) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation Sulfonamide derivative
KR101566171B1 (en) 2007-03-09 2015-11-06 삼성전자 주식회사 Method and apparatus for digital rights management
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
US8232292B2 (en) 2007-07-02 2012-07-31 Asahi Kasei Pharma Corporation Sulfonamide compound and crystal thereof
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
MX2010002426A (en) * 2007-08-29 2010-04-27 Senju Pharma Co Agent for promoting corneal endothelial cell adhesion.
CA2725416A1 (en) * 2008-05-12 2009-11-19 Amnestix, Inc. Compounds for improving learning and memory
NZ590067A (en) 2008-06-24 2012-09-28 Sanofi Aventis Bi-and polycyclic substituted isoquinoline and isoquinolinone derivatives as rho kinase inhibitors
PE20110059A1 (en) 2008-06-24 2011-02-15 Sanofi Aventis Isoquinolines and substituted isoquinolinones as inhibitors of rho kinase
PE20110054A1 (en) 2008-06-24 2011-02-15 Sanofi Aventis Isoquinolines and 6-substituted isoquinolinones
KR20110042054A (en) 2008-07-24 2011-04-22 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Prophylactic or therapeutic agent for axial myopia
CA2737738A1 (en) * 2008-09-18 2010-03-25 Astellas Pharma Inc. Heterocyclic carboxamide compounds
EP2177218A1 (en) 2008-10-15 2010-04-21 Medizinische Universität Wien Regenerative therapy
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PL2414356T3 (en) 2009-04-03 2016-02-29 Hoffmann La Roche Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
EP3235901A1 (en) 2009-10-16 2017-10-25 The Scripps Research Institute Induction of pluripotent cells
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN102188697B (en) * 2010-03-03 2014-11-05 中国医学科学院药物研究所 Application of recombinant human Rho kinase to preparation of medicaments
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EP2655601A4 (en) 2010-12-22 2014-09-10 Fate Therapeutics Inc Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
PT2672967T (en) 2011-02-07 2018-12-07 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
US9273006B2 (en) * 2012-05-08 2016-03-01 Syddansk Universitet Anabolic compounds for treating and preventing bone loss diseases
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
RU2681730C2 (en) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Anti-kit antibodies and uses thereof
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US20160339018A1 (en) 2013-04-24 2016-11-24 Kyushu University, National University Corporation Therapeutic agent for ocular fundus disease
WO2014177699A1 (en) * 2013-05-03 2014-11-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Rhoa (rock) inhibitors for the treatment of enflammatory bowel disease
SG11201509982UA (en) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
RU2699289C2 (en) 2013-08-26 2019-09-04 Байонтек Рисерч Энд Дивелопмент, Инк. Nucleic acids encoding human antibodies to sialyl-lewisa
MX2017011194A (en) 2015-03-03 2018-04-10 Kymab Ltd Antibodies, uses & methods.
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
US20180296474A1 (en) 2015-10-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
AU2016365318A1 (en) 2015-12-02 2018-06-21 Board Of Regents, The University Of Texas System Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
US20190275084A1 (en) 2016-11-03 2019-09-12 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3065300A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
AU2018277838A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
WO2019014322A1 (en) * 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
US20190111164A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Human antibodies to tn antigen

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS6361942B2 (en) 1981-06-01 1988-11-30
JPH0144188B2 (en) 1982-01-12 1989-09-26 Asahi Kasei Kogyo Kk
JPH0227992B2 (en) 1982-01-14 1990-06-20 Asahi Kasei Kogyo Kk Isokinorinsuruhonirukagobutsu
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPH0428698B2 (en) 1982-11-18 1992-05-15 Asahi Kasei Kogyo Kk
JPH0429666B2 (en) 1983-10-13 1992-05-19
DE3583287D1 (en) 1984-12-27 1991-07-25 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds.
JPH0481986B2 (en) 1984-12-27 1992-12-25 Asahi Kasei Kogyo Kk
JPH053851B2 (en) 1985-04-02 1993-01-18 Asahi Kasei Kogyo Kk
JPH0680054B2 (en) 1985-06-19 1994-10-12 吉富製薬株式会社 Piperidine derivatives
JPH062741B2 (en) 1985-10-29 1994-01-12 弘義 日高 Secondary isoquinoline sulfonamide derivative
WO1990005723A1 (en) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use
JP2770497B2 (en) * 1988-11-24 1998-07-02 吉富製薬株式会社 Trans-4-amino (alkyl) -1-pyridinium carbamoyl cyclohexane compounds and their pharmaceutical use
JP2720348B2 (en) * 1989-03-30 1998-03-04 旭化成工業株式会社 Brain cell function disorder improving agent
JP3408546B2 (en) * 1991-02-19 2003-05-19 旭化成株式会社 Anti-asthma agent
JP2864489B2 (en) * 1991-02-27 1999-03-03 吉富製薬株式会社 Asthma treatment agent
JP3275389B2 (en) * 1991-09-06 2002-04-15 三菱ウェルファーマ株式会社 4-amino (alkyl) cyclohexane-1-carboxylic acid amide
EP0641781B1 (en) 1991-09-06 2000-07-26 Yoshitomi Pharmaceutical Industries, Ltd. 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
JPH05273821A (en) 1992-03-24 1993-10-22 Nippon Steel Corp Electrostatic image forming device
JP3265695B2 (en) * 1992-05-12 2002-03-11 三菱ウェルファーマ株式会社 4-substituted amino (alkyl) cyclohexane-1-carboxylic acid amide
JP2893029B2 (en) * 1992-08-10 1999-05-17 旭化成工業株式会社 Cardioprotective agent
JPH0680569A (en) * 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd Antithrombotic agent
JPH06289679A (en) * 1993-04-01 1994-10-18 Hitachi Metals Ltd Image forming method
JP3464012B2 (en) * 1993-04-05 2003-11-05 旭化成株式会社 Spirit symptomatic treatment agent
JPH0741424A (en) * 1993-07-28 1995-02-10 Asahi Chem Ind Co Ltd Anti-inflammatory agent
JPH07277979A (en) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd Therapeutic or preventive agent for hyperviscosity syndrome
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
EE9900050A (en) * 1996-08-12 1999-08-16 Yoshitomi Pharmaceutical Industries, Ltd. A pharmaceutical agent containing a Rho kinase inhibitor

Also Published As

Publication number Publication date
BG63992B1 (en) 2003-09-30
NZ334613A (en) 2002-02-01
KR100595740B1 (en) 2006-07-03
US6451825B1 (en) 2002-09-17
CZ301044B6 (en) 2009-10-21
PL331561A1 (en) 1999-07-19
NZ513800A (en) 2001-09-28
DE69737631D1 (en) 2007-05-31
ES2286834T3 (en) 2007-12-01
KR100576148B1 (en) 2006-05-03
BG107645A (en) 2004-05-31
BG63991B1 (en) 2003-09-30
NO990622D0 (en) 1999-02-10
RU2003103606A (en) 2004-08-27
PT956865E (en) 2007-07-30
HU9903694A3 (en) 2002-10-28
US6218410B1 (en) 2001-04-17
HK1022436A1 (en) 2007-12-14
DK0956865T3 (en) 2007-09-03
DK0956865T4 (en) 2010-11-22
AT359822T (en) 2007-05-15
KR20000029918A (en) 2000-05-25
EP0956865A1 (en) 1999-11-17
US20020032148A1 (en) 2002-03-14
US6906061B2 (en) 2005-06-14
WO1998006433A1 (en) 1998-02-19
SI0956865T2 (en) 2011-04-29
BG107195A (en) 2003-05-30
DE69737631T3 (en) 2011-08-18
EP0956865B2 (en) 2010-08-18
HU229864B1 (en) 2014-10-28
JP3669711B2 (en) 2005-07-13
CA2263425C (en) 2008-09-30
SI0956865T1 (en) 2007-10-31
EP0956865B1 (en) 2007-04-18
EE9900050A (en) 1999-08-16
EP0956865A4 (en) 2001-05-16
CN100389828C (en) 2008-05-28
RU2206321C2 (en) 2003-06-20
CA2263425A1 (en) 1998-02-19
ES2286834T5 (en) 2011-01-31
NO990622L (en) 1999-04-12
AU738620B2 (en) 2001-09-20
IS4973A (en) 1999-02-11
BR9711154A (en) 1999-08-17
AU3785197A (en) 1998-03-06
BG103246A (en) 2000-05-31
US20030134775A1 (en) 2003-07-17
RU2003104284A (en) 2004-08-27
CZ46099A3 (en) 1999-07-14
DE69737631T2 (en) 2007-12-27
CN1233188A (en) 1999-10-27
KR20050055022A (en) 2005-06-10
HU9903694A2 (en) 2000-03-28

Similar Documents

Publication Publication Date Title
DK0956865T4 (en) Medications comprising Rho kinase inhibitor
GB2331873B (en) Modular plug having compensating insert
PL341824A1 (en) Aryl-condensed azapolycyclic compounds
GB9722520D0 (en) Compounds
HU9903759A3 (en) Abtimicrobial compositions
PL341372A1 (en) Cellecoxibe containing compositions
EP0914330A4 (en) Novel compounds
EP0961618A4 (en) Novel compounds
GB9612884D0 (en) Novel compounds
EP0904104A4 (en) Novel compounds
SG82568A1 (en) Ink compositions
GB9611422D0 (en) Coated scale inhibitors
HU9901620A3 (en) Antifungal compositions containing itraconazole
PL184802B1 (en) Refreshing compositions
PL183144B1 (en) Pharmaceutic composition containing the proton-pump inhibitors
GB9520490D0 (en) Compounds
IL141867D0 (en) 4-aminopyrrolopyrimidines as kinase inhibitors
AP9701165A0 (en) C-4 adnosine kinase inhibitors
GB9601067D0 (en) Novel compounds
ZA9701542B (en) Coating composition comprising a bicyclo- or spiro-orthoester-functional compound
GB9601599D0 (en) Radiation-curable compositions
EP0954331A4 (en) Novel compounds
PL330972A1 (en) Tetrahydrolypstatin containing compositions
HK1057004A1 (en) Reflux inhibitors
GB9504995D0 (en) Compositions